B · Normal
On November 2, UniQure’s U.S. stocks rose 12% before the market opened after the FDA accepted priority review for UniQure’s Huntington’s disease gene therapy application.
Related telegraphs
On November 2, Alphabet planned to raise 6 billion euros through the issuance of
11-02 21:47
On November 2, S&P 500 index futures rose 0.6%, hitting a pre-market high.
11-02 21:39
On November 2, Moody's Ratings confirmed Oracle's Baa2 rating, involving its new
11-02 21:36
On November 2, Infineon and Qualcomm cooperated in the field of vehicle-mounted
11-02 21:33
On November 2, JPMorgan Chase resumed coverage of L3Harris Technologies with an
11-02 21:30
On November 2, Lumen expanded its cooperation with Microsoft to jointly sell ent
11-02 21:30
Comments